エピソード

  • Benefits of Endovascular Therapy for Post-Thrombotic Syndrome; Sex Hormones & CV Risk; Asundexian & Stroke Risk; Cardiorespiratory Fitness & Longer Lifespans

    Benefits of Endovascular Therapy for Post-Thrombotic Syndrome; Sex Hormones & CV Risk; Asundexian & Stroke Risk; Cardiorespiratory Fitness & Longer Lifespans
    2026/04/29
    In this week's View, Dr. Eagle looks at endovascular therapy for post-thrombotic syndrome and how it reduces severity and improves quality of life. He then explores current evidence and strategies to address sex hormone-associated thrombotic and cardiovascular risk. Next, Dr. Eagle examines the OCEANIC-STROKE trial which studied asundexian and its potential to lower recurrent stroke risk in patients with noncardioembolic stroke or transient ischemic attack. Finally, Dr. Eagle asks the question, is high cardiorespiratory fitness associated with longer lifespan and lower multimorbidity? Subscribe to Eagle's Eye View  
    続きを読む 一部表示
    9 分
  • Early Surgery for AS; Blood Pressure Trajectories; PCI vs Medical Therapy for Chronic Coronary Disease

    Early Surgery for AS; Blood Pressure Trajectories; PCI vs Medical Therapy for Chronic Coronary Disease
    2026/04/22

    In this week's View, Dr. Eagle examines early surgery for asymptomatic patients with severe aortic stenosis. He then reviews evidence linking blood pressure trajectories and rapid control to significantly improved outcomes. Finally, he compares percutaneous coronary intervention with medical therapy for chronic total occlusion in patients with chronic coronary disease.

    Subscribe to Eagle's Eye View  

    続きを読む 一部表示
    8 分
  • Caring for Patients: Cardiogenic Shock Survivorship, Masters Athletes, Medicare Spending on Semaglutide, GDMT and Veterans

    Caring for Patients: Cardiogenic Shock Survivorship, Masters Athletes, Medicare Spending on Semaglutide, GDMT and Veterans
    2026/04/15

    In this week's View, Dr. Eagle explores four recent articles that examine how we care for patients. First, Dr. Eagle looks at a new state-of-the-art review that outlines a multidisciplinary framework for cardiogenic shock survivorship. He then analyzes the new Joint Clinical Statement focusing on Masters athletes with abnormal cardiovascular findings, followed by details on a study of how participation in the BALANCE Model will impact Medicare spending on semaglutide. Finally, Dr. Eagle discusses how modifiable barriers may improve access to quadruple guideline-directed medical therapy for veterans with heart failure with reduced ejection fraction.

     Subscribe to Eagle's Eye View  

    続きを読む 一部表示
    9 分
  • Top Takeaways from ACC.26

    Top Takeaways from ACC.26
    2026/04/08
    In this week's View, Dr. Eagle highlights trials from the recently held ACC Scientific Sessions which took place in New Orleans, March 28-30. Important studies discussed include: CHAMPION-AF: Left atrial appendage closure vs. anticoagulation for AFib VESALIUS-CV: Evolocumab reduces CV risk in diabetic patients without ASCVD Ez-PAVE: Hitting lower LDL-C target reduces major CV events PRO-TAVI: Should high-risk patients undergo PCI before TAVI? SMART-DECISION: Discontinuing beta-blockers safe 1 year post MI For stable patients GoFreshRx: How home-delivered DASH groceries improve blood pressure (BP) and LDL-C THRIVE: Exploring the positive effects of a culturally tailored "food-is medicine" program on lowering BP  
    続きを読む 一部表示
    11 分
  • New ACC/AHA Dyslipidemia Guidelines Released

    New ACC/AHA Dyslipidemia Guidelines Released
    2026/03/18

    In this week's View, Dr. Eagle looks at data from the STS/ACC TVT Registry on off-label transcatheter valve interventions that demonstrate reduced residual tricuspid regurgitation (TR) and improved quality of life. He then explores the REVNOVATE-COMPLEX-PCI study that investigates the benefits of intravascular imaging guidance for five years. Finally, Dr. Eagle summarizes the ACC/AHA's newly released clinical guidelines for managing dyslipidemia.

     Subscribe to Eagle's Eye View  

    続きを読む 一部表示
    8 分
  • Beta-Blocker vs. Calcium-Channel Blocker in HCM

    Beta-Blocker vs. Calcium-Channel Blocker in HCM
    2026/03/11
    In this week's View, Dr. Eagle looks at the differential effect of bisoprolol versus verapamil in nonobstructive hypertrophic cardiomyopathy (HCM) treatment. He then explores lower heart failure (HF) hospitalization risk in patients with type 2 diabetes, comparing GLP-1RAs to DPP-4 inhibitors and similar outcomes with SGLT-2 inhibitors. Dr. Eagle then examines the use of shared decision-making and decision aids in percutaneous left atrial appendage occlusion (LAAO). Finally, the iModern trial, which compares immediate percutaneous coronary intervention (PCI) guided by instantaneous wave-free ratio (iFR) and deferred PCI guided by cardiac stress magnetic resonance imaging (MRI) in patients with STEMI and multivessel disease, is discussed.  Subscribe to Eagle's Eye View  
    続きを読む 一部表示
    9 分
  • Increased Mortality and TAVR; Wine Intake and CV Risk; PVI & Drug-Refractory Paroxysmal Atrial Fibrillation

    Increased Mortality and TAVR; Wine Intake and CV Risk; PVI & Drug-Refractory Paroxysmal Atrial Fibrillation
    2026/03/04
    In this week's View, Dr. Eagle looks at increased one-year mortality in younger patients undergoing transcatheter aortic valve replacement (TAVR). He then explores the PREDIMED trial which found that adherence to the Mediterranean diet plus moderate wine intake was associated with reduced cardiovascular risk and mortality. Finally, Dr. Eagle examines 20-year outcomes for pulmonary vein isolation (PVI) in patients with drug-refractory paroxysmal atrial fibrillation (AFib).  Subscribe to Eagle's Eye View  
    続きを読む 一部表示
    7 分
  • Self-Expanding TAVR vs Surgery; Ticagrelor vs Prasugrel in PCI; New Guidelines for Treatment of Acute Pulmonary Embolism

    Self-Expanding TAVR vs Surgery; Ticagrelor vs Prasugrel in PCI; New Guidelines for Treatment of Acute Pulmonary Embolism
    2026/02/24
    In this week's View, Dr. Eagle looks at findings from the Evolut Low Risk trial in which self-expanding transcatheter aortic valve replacement (TAVR) versus surgery at six years in low-risk patients with aortic stenosis (AS) is considered. He then explores the TUXEDO-2 Trial evaluating ticagrelor versus prasugrel in percutaneous coronary intervention patients with diabetes and multivessel coronary disease (MVD). Finally, Dr. Eagle examines the first-ever release of the AHA/ACC guideline for treatment and management of acute pulmonary embolism (PE) in adults.  Subscribe to Eagle's Eye View  
    続きを読む 一部表示
    8 分